The unparalleled patient care we deliver begins with original ideas and trailblazing research. The Icahn School of Medicine at Mount Sinai (ISMMS) is home to dozens of top-funded research institutes, centers, and laboratories, collaborating across disciplines to make swift and meaningful advances in medicine. In keeping with our passion for intellectual inquiry, our patient-centered philosophy, and our track record of clinical breakthroughs, we are making medical history, developing new treatments for those most in need and introducing a new era of precision medicine that will help patients worldwide.
On the frontline of medical research, we investigate, discover, and develop treatments and technologies in a number of critically important areas. A few of our recent milestones include:
- Identifying first common gene variant linked to autism
- Performing the first successful surgical composite tracheal transplant
- Identifying a gene in the brain–OLIG2–that may play a causal role in the development of schizophrenia
- Performing the first U.S. implantation of a new device for aortic stenosis
The Icahn School of Medicine receives some of the highest National Institutes of Health (NIH) funding nationwide for our peer-reviewed research. We also attract large donors for many of our comprehensive research initiatives. With a vital and ever-expanding presence throughout New York City and beyond, this support is likely to keep growing. A few examples of our expansive research include:
The Friedman Brain Institute
Through innovative studies of the brain and spinal cord, our researchers have made impressive progress in understanding how the nervous system functions under normal conditions and during neurological malfunction. The Friedman Brain Institute recognizes the nervous system as the last frontier of the molecular revolution in medicine, making basic science breakthroughs and translating them into fundamentally new and improved treatments of brain and spinal cord disorders.
Ronald M. Loeb Center for Alzheimer’s Disease
The Mount Sinai Health System's work with Alzheimer's disease spans a multi-site network of clinics, hospitals, and practices. We treat more than 3,000 patients every year, and our translational research programs have been awarded in excess of $200 million from NIH and other agencies. The Loeb Center's mission is to develop state-of-the-art Alzheimer's disease care through innovations in genomics, neurobiology, stem cell engineering, and other disciplines. The Loeb Center is a major player in advancing the diagnosis, prevention, and treatment of Alzheimer's disease, making a significant impact in New York and globally. These efforts build on the Mount Sinai legacy as an early treatment model and NIH Alzheimer's Disease Research Center.
Research Collaboration and Partnerships
We know that biomedical advances cannot be achieved in isolation, which is why we embrace the collaborative process and have created partnerships with some of the world’s greatest pioneers in scientific innovation, including:
Rensselaer Polytechnic Institute (RPI)
We forged this powerful partnership to combine our leadership in biomedical research and patient care with RPI’s excellence in engineering and computational sciences.
Google Life Sciences
Our academic partnership with Google Life Sciences offers our MD and MD/PhD students advanced training and exploration from a leader in life science breakthroughs.